Simplex Trading
SKYE icon

Simplex Trading’s Skye Bioscience SKYE Stock Holding History

Simplex Trading’s Portfolio SKYE Stock Details SKYE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-6,331
Closed -$5.16K – 10376
2025
Q4 		$4.75K Buy
+6,331
New +$9.25K ﹤0.01% 7464
2025
Q3 		– Sell
-1,169
Closed -$4.42K – 10278
2025
Q2 		$4K Buy
+1,169
New +$2.42K ﹤0.01% 7917
2025
Q1 		– Sell
-17
Closed – – 9896
2024
Q4 		$0 Buy
+17
New +$71 ﹤0.01% 9828

Other funds holding SKYE

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Simplex Trading's SKYE Position: Q1 2026 in Review

Simplex Trading sold out of Skye Bioscience (SKYE) in Q1 2026, closing a stake of 6,331 shares — an estimated $5.16K sold.

Simplex Trading first reported a position in SKYE in Q4 2024 and held it in 3 quarters. The position peaked at $4.75K in Q4 2025. 39 funds tracked by Wall St. Rank hold SKYE as of Q1 2026.

  • Simplex Trading reported no remaining Skye Bioscience position as of Q1 2026 after selling out during the quarter.
  • Simplex Trading sold 6,331 Skye Bioscience shares in Q1 2026, an estimated $5.16K.
  • Simplex Trading first reported a position in Skye Bioscience in Q4 2024 and held it in 3 quarters.
  • Simplex Trading's Skye Bioscience position peaked at $4.75K in Q4 2025.
  • 39 funds tracked by Wall St. Rank held Skye Bioscience as of Q1 2026.

Based on Simplex Trading's 13F filing for Q1 2026, filed 14 May 2026.